Investors are closely watching Eli Lilly Eli lilly GLP1 peptides & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Experts are expecting strong performance driven by the strong demand of Lilly's blockbuster treatments, particularly its insulin portfolio. However, there are also concerns abo